Skip to search formSkip to main contentSkip to account menu

aducanumab

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Antibodies, Monoclonal, Humanized

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Clinical Trials of the Anti-Amyloid Therapy, Aducanumab, Are Stopped After Disappointing Results
2019
2019
Complex Simplicity and Hirschsprung's Disease.
Science envy comes in many flavors, and it is particularly easy to envy those who are privileged to discover simple stories. A… 
2018
2018
Aducanumab titration dosing regimen: 24-month analysis from PRIME, a randomized, double-blind, placebo-controlled Phase 1b study in patients with prodromal or mild Alzheimer’s disease (S2.003)
Objective: We report 24-month data for fixed-dose and titration cohorts, including 12 months from the placebo-controlled period… 
2018
2018
New Data from Phase 1 b Study of Investigational Alzheimer ’ s Disease Treatment
  • 2018
  • Corpus ID: 4091257
In the Phase 1b LTE, the most commonly reported adverse events were headache, fall and amyloid-related imaging abnormalit ies… 
2017
2017
From Nose to Brain: The Promise of Peptide Therapy for AlzheimerâÂÂsDisease and Other Neurodegenerative Diseases
The pathological hallmarks of Alzheimer’s disease (AD) are the deposition of extracellular senile plaques resulting from amyloid… 
2017
2017
Titration dosing of aducanumab: Results of a 12-month interim analysis from a randomized, double-blind, placebo-controlled Phase 1b study (PRIME) in patients with prodromal or mild Alzheimer’s…
Objective: To report interim results from a Phase 1b study (PRIME) for fixed-dose and titrated aducanumab. Background: Aducanumab… 
2016
2016
CLINICAL DEMENTIA RATING-SUM OF BOXES RESPONDER ANALYSIS IN PRIME: A RANDOMIZED PHASE 1B STUDY OF THE ANTI-AMYLOID BETA MONOCLONAL ANTIBODY ADUCANUMAB (BIIB037)
Review
2016
Review
2016
Title : Emerging drugs to reduce abnormal β-amyloid protein in Alzheimer ’ s disease patients
iRGD (internalizing RGD) with high affinity to αν integrins was reported to enhance tumor penetrability by binding to neuropilin… 
2016
2016
Post-Hoc Analysis of Early AD Subjects Meeting Phase 3 Entry Criteria in PRIME, a Phase 1b Study of the Anti-Amyloid Beta Antibody Aducanumab (BIIB037) (P4.007)
OBJECTIVE: To report interim data from the ongoing Phase 1b study (PRIME) in patients with Early Alzheimer’s Disease (AD) with… 
2015
2015
Aducanumab: Hype, or Headway for the Alzheimer’s Amyloid Hypothesis?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)